Author: Jonathan Smith
Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here! Out of the office, I travel, play video games and board games, drink beer and play the piano.
Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential
Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial
First Ever Ebola Vaccine Gets Conditional EU Approval
First Results Out for Off-the-Shelf CAR-T Therapy in Solid Tumors
Argenx Raises Whopping €502M in Global Offering
Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II
It’s News Roundup Time! NASH, Milk Microfluidics, and More …
Avantium Builds 10-Ton Demonstration Plant to Produce Bioplastics
€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics
UK Biotech Launched to Target ‘Dark Antigens’ with Cancer Vaccines
